The purpose of the Biostatistics and Bioinformatics Core C is to provide consultation and collaboration on quantitative methods on all SPORE Projects, Developmental Projects, and Cores A and B. Successful collaboration between the project leaders and the biostatisticians and computational biologists in this SPORE, as well as members of the other Cores, is essential to achieve the goals of the projects. Members of this core will provide support for the design, analysis, and reporting of laboratory, animal, translational, genomic, and clinical studies. Depending on the project, these collaborations could range from short consultations to large collaborative projects, and will include assistance in preparation of grant applications and manuscripts related to the SPORE projects. The Core members will also provide statistical mentoring to the researchers, with a particular emphasis on Career Development Awardees and Developmental Project Investigators. Important for the success of the SPORE is the coordination of data management and quality control procedures. The biostatisticians and computational biologists are an integral part of this process at the DFCI, and will continue to provide input on the existing procedures, as well as recommendations on additional computational infrastructure, which might be necessary for this SPORE. To achieve the goals of the SPORE, we propose the following specific aims:
Specific Aim 1. To provide biostatistical collaboration for SPORE Projects, Developmental Projects, and Cores. This includes all aspects of design, conduct, analysis, and reporting of laboratory and clinical protocols, including coordination of laboratory results with patient characteristics and outcomes from the clinical studies.
Specific Aim 2. To provide consulting and statistical education to SPORE researchers.
Specific Aim 3. To provide or recommend supporting computational infrastructure. This includes collaboration with the multiple myeloma clinical research coordinators (CRC) and the data specialist at the Quality Assurance Office for Clinical Trials (QACT) on the collection of data, forms development, data processing, and quality assurance of clinical trials data. We will also provide consultation on computer databases, moving data between data bases for laboratory, animal, and relevant clinical studies Specific Aim 4. To provide bioinformatic support for analysis of high throughput transcriptional and genomic studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Ye, Shuai; Lawlor, Matthew A; Rivera-Reyes, Adrian et al. (2018) YAP1-Mediated Suppression of USP31 Enhances NF?B Activity to Promote Sarcomagenesis. Cancer Res 78:2705-2720
Hunter, Zachary R; Xu, Lian; Tsakmaklis, Nickolas et al. (2018) Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv 2:2937-2946
Szalat, R; Samur, M K; Fulciniti, M et al. (2018) Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia 32:111-119
Bolli, Niccolò; Maura, Francesco; Minvielle, Stephane et al. (2018) Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 9:3363
Gullà, A; Hideshima, T; Bianchi, G et al. (2018) Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia 32:996-1002
Mazzotti, Céline; Buisson, Laure; Maheo, Sabrina et al. (2018) Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv 2:2811-2813
Samur, Mehmet Kemal; Minvielle, Stephane; Gulla, Annamaria et al. (2018) Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia 32:2626-2635
Xu, Yan; Deng, Shuhui; Mao, Xuehan et al. (2018) Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk 18:422-430
Michallet, M; Chapuis-Cellier, C; Dejoie, T et al. (2018) Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia 32:376-382
Ray, A; Das, D S; Song, Y et al. (2018) Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma. Leukemia 32:843-846

Showing the most recent 10 out of 407 publications